Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann Surg Oncol. 2017 Dec;24(13):3954-3963. doi: 10.1245/s10434-017-6098-6. Epub 2017 Oct 4.
The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established.
A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (≥ 50% of viable residual tumor cells). Uni- and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS).
For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS.
The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.
术前治疗的病理反应对十二指肠腺癌(DA)和壶腹腺癌(AMPA)患者的预后影响尚未确定。
对 1993 年至 2015 年间接受根治性切除术的 266 例 DA(n=97)或 AMPA(n=169)患者进行了回顾性分析。对于接受术前治疗的患者,系统评估了病理反应并分为主要反应(存活肿瘤细胞的 0-49%)或次要反应(≥50%存活肿瘤细胞)。进行单变量和多变量分析以确定病理反应和疾病特异性生存(DSS)的预测因素。
对于 79 例接受术前治疗的患者(DA:n=34;AMPA:n=45),同时使用放疗(80%,67/79)是主要病理反应的唯一独立预测因素(比值比[OR]8.17;95%置信区间[CI]1.85-58.2;P=0.005)。主要病理反应患者的 5 年 DSS 率优于次要病理反应患者(DA:65%比 25%;P=0.028;AMPA:85%比 43%;P=0.016)。在对 79 例接受术前治疗的患者进行的 DSS 多变量分析中,主要病理反应是 DSS 改善的唯一预测因素(风险比[HR]2.88;95%CI 1.41-5.98;P=0.004)。在整个队列的 DSS 多变量分析中,病理分期 2 期或更低是 DSS 更好的唯一预测因素。
术前治疗的主要病理反应预测了 DA 和 AMPA 切除后的 DSS 改善,并且可能是 DA 和 AMPA 切除后的新预后因素。